Diagnostic and prognostic utility of measuring tumor necrosis factor in the peripheral circulation of patients with immune-mediated sensorineural hearing loss

Archives of Otolaryngology - Head and Neck Surgery

Volumn 138, Issue 11, 2012, Pages 1052-1058

  Svrakic, Maja ^a   Pathak, Shresh ^a,b   Goldofsky, Eliot ^a,b   Hoffman, Ronald ^e   Chandrasekhar, Sujana S ^e   Sperling, Neil ^e,f   Alexiades, George ^e   Ashbach, Matthew ^a   Vambutas, Andrea ^a,b,c,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Otolaryngology ^*  (United States)

^c Feinstein Institute of Medical Research   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f Downstate Health Sciences University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; MESSENGER RNA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALGORITHM; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; IMMUNE MEDIATED SENSORINEURAL HEARING LOSS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PERCEPTION DEAFNESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL CIRCULATION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TERTIARY HEALTH CARE;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HEARING LOSS, SENSORINEURAL; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84869776959     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/2013.jamaoto.76     Document Type: Article

References (18)

1. Ruckenstein MJ. Autoimmune inner ear disease. Curr Opin Otolaryngol Head Neck Surg. 2004;12(5):426-430. (Pubitemid 39287572)
2. Hashimoto S, Billings P, Harris JP, Firestein GS, Keithley EM. Innate immunity contributes to cochlear adaptive immune responses. Audiol Neurootol. 2005; 10(1):35-43. (Pubitemid 40069613)
3. Lorenz RR, Solares CA, Williams P, et al. Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss. J Neuroimmunol. 2002;130(1-2):173-178. (Pubitemid 35240004)
4. Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol. 2005;26(5):903-907. (Pubitemid 41330705)
5. Harris JP, Weisman MH, Derebery JM, et al. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA. 2003;290(14):1875-1883. (Pubitemid 37430604)
6. Matteson EL, Choi HK, Poe DS, et al. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005;53(3):337-342. (Pubitemid 40799870)
7. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001; 22(5):619-624. (Pubitemid 32845635)
8. Van Wijk F, Staecker H, Keithley E, Lefebvre PP. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol. 2006;11(6):357-365. (Pubitemid 44610323)
9. Ren J, Li H, Lu Y. The determinations of tumor necrosis factor and interleukin 6 in serum of patients with sudden sensorineural hearing loss [in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1998;12(7):311-313.
10. Keithley EM, Wang X, Barkdull GC. Tumor necrosis factor alpha can induce recruitment of inflammatory cells to the cochlea. Otol Neurotol. 2008;29(6):854-859.
11. Wang X, Truong T, Billings PB, Harris JP, Keithley EM. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol. 2003;24(1):52-57. (Pubitemid 36169365)
12. Lobo D, Trinidad A, García-Berrocal JR, Verdaguer JM, Ramírez-Camacho R. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis. Eur Arch Otorhinolaryngol. 2006;263(7):622-626. (Pubitemid 43962183)
13. Kassner SS, Schöttler S, Bonaterra GA, et al. Proinflammatory and proadhesive activation of lymphocytes and macrophages in sudden sensorineural hearing loss. Audiol Neurootol. 2011;16(4):254-262.
14. Süslü N, Yilmaz T, Gürsel B. Utility of anti-HSP 70, TNF-alpha, ESR, antinuclear antibody, and antiphospholipid antibodies in the diagnosis and treatment of sudden sensorineural hearing loss. Laryngoscope. 2009;119(2):341-346.
15. Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol. 2011;186(3):1870-1879.
16. Vambutas A, DeVoti J, Goldofsky E, Gordon M, Lesser M, Bonagura V. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS One. 2009;4(4): e5293.
17. Niparko JK, Wang NY, Rauch SD, et al AIED Study Group. Serial audiometry in a clinical trial of AIED treatment. Otol Neurotol. 2005;26(5):908-917. (Pubitemid 41330706)
18. Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience. Semin Arthritis Rheum. 2004;34(2):544-548. (Pubitemid 40288131)